前列腺干细胞抗原在人前列腺癌组织中的表达及意义

目的　探讨前列腺干细胞抗原 (PSCA)在国人前列腺癌 (PCa)组织中表达的临床意义。　方法　采用免疫组织化学 (IHC)和核酸原位杂交 (ISH)方法检测 4 0例PCa、2 0例良性前列腺增生(BPH)和 2 0例前列腺上皮内瘤 (PIN)组织标本PSCA蛋白和mRNA表达 ,半定量法计算PSCA阳性表达细胞百分数和阳性表达强度 ,比较各组织间表达水平的差异及其与PCa分级、临床分期之间的关系。　结果　PCa、BPH、PIN组织PSCA中度阳性到强阳性表达分别为 85 % (34/ 4 0 )、2 0 % (4/ 2 0 )和35 % (7/ 2 0 ) ;PCa组织PSCA表达水平与BPH和PIN比较差异有统计学意义 (P <0 .0 5 ) ,BPH与PIN比较差异无统计学意义 (P >0 .0 5 ) ;PCa组织PSCA表达水平随Gleason评分及临床分期增加而升高。　结论　人PCa组织有PSCA蛋白质和mRNA的过表达 ,且与PCa病理分级、临床分期呈正相关 ,可能对PCa的诊断及判断预后有潜在价值。     

前列腺干细胞抗原在前列腺癌中的表达及其与雄激素受体、雌激素受体联合检测的意义

目的探讨前列腺干细胞抗原(PSCA)在前列腺癌(PCa)和良性前列腺增生(BPH)中的表达,及其与雄激素受体(AR)、雌激素受体(ER)联合检测的临床意义。方法应用免疫组化方法检测PSCA、AR和ER在50例PCa和30例BPH标本中的表达。结果 PSCA在PCa中高表达,在BPH中少量表达或不表达,PSCA表达的变化与PCa的Gleason评分具有明显相关性。AR在PCa中的表达与其分化程度无明显相关性,与PSCA无明显相关性。ER在BPH中表达阳性率为100%,且普遍强阳性,在PCa中表达的阳性率为12%,均与PSCA的表达呈负相关。结论 PSCA在前列腺细胞增殖、肿瘤形成的演进过程中发挥重要作用,联合检测PSCA和ER有助于PCa和BPH的诊断和治疗。     

survivin蛋白在前列腺癌中的表达及其与肿瘤细胞凋亡的关系

目的 :探讨新的凋亡基因survivin蛋白在前列腺癌 (PCa)的表达及其与肿瘤细胞凋亡的关系。　方法 :采用免疫组化SP法和DNA原位未端标记TUNEL法分别测定 4 2例PCa组织及 10正常前列腺 (NP)组织中survivin蛋白的表达和细胞凋亡。　结果 :survivin蛋白在PCa中的阳性表达为 80 .5 9% ,与病理分级、临床分期和淋巴结转移密切相关 (P <0 .0 5 ) ,而NP中无阳性表达 ;PCa组织及NP组织中细胞凋亡指数 (AI)分别为 3.0 3± 1.33、1.0 7± 0 .77,其差异有显著意义 (P <0 .0 5 ) ;survivin蛋白的表达与细胞AI呈负相关 (r=- 0 .6 79,P <0 .0 0 1)。　结论 :survivin蛋白的异常表达而引起的细胞凋亡抑制 ,在PCa的发生、发展中起一定的作用 ;联合检测survivin蛋白和AI,有助于对肿瘤细胞的分化程度作出正确评价 ,以指导临床治疗及估计预后     

良性增生前列腺组织中TGF_(β1)mRNA和蛋白的表达

目的 :在转录和翻译水平探讨转化生长因子 β1(TGFβ1 )在良性前列腺增生症 (BPH)前列腺组织中的表达及意义。方法 :应用原位杂交和免疫组织化学法对 2 2例 BPH和 10例正常前列腺 (NP)组织标本中 TGFβ1的表达进行定性、定位检测。结果 :BPH前列腺和 NP组织的上皮和间质都有明显的 TGFβ1 m RNA表达 ,其表达在 BPH和 NP间差异无显著性意义 (P >0 .0 5 ) ;在两组内 ,基质细胞 TGFβ1 m RNA表达明显高于上皮细胞 (P<0 .0 1)。 BPH前列腺和 NP的上皮组织中 TGFβ1 蛋白表达较弱 ,且两者之间差异无显著性意义 (P >0 .0 5 ) ;间质中 TGFβ1 表达均为阳性 ,BPH前列腺间质中阳性表达显著强于 NP的间质 (P <0 .0 1) ,以基质为主要成分的增生结节中表达更高。结论 :TGFβ1 是导致 BPH前列腺间质增生的重要物质 ,启动 BPH发生发展的因素在转录后水平调控 TGFβ1 的表达。     

前列腺癌组织中端粒酶hTRT基因表达及意义

目的 探讨前列腺癌组织中端粒酶hTRT基因的表达及意义。方法 应用原位分子杂交技术,对47例前列腺癌（PCa)、21例良性前列腺增生（BPH）和10例正常前列醇（NP）组织中微粒酶hTRT基因进行检测和定位,并运用图像分析系统对hTRT表达水平与PCa分化程度的相关性进行研究。结果 端粒酶hTRT基因在PCa中表达阳性率为93．6％,表达强度与肿瘤细胞的分化程度显著相关：未分化腺癌＞低分化腺癌＞中分化腺癌＞高分化腺癌;癌旁组织中hTRT基因表达率为8．5％,在肿瘤组织和癌旁组强中差别有极显著性意义（P＜0．01）。端粒酶hTRT基因表达水平与肿瘤细胞的分布定位一致,NP组织及BPH组织中端粒酶hTRT基因表达均为阴性。结论 原位杂交检测端粒酶hTRT基因对PCa细胞水平的定位诊断具有重要意义,端粒酶hTRT有可能成为PCa诊断有新标志物及治疗新靶点。     

前列腺癌组织中P504S的表达及其与血清前列腺特异抗原的关系

目的 探讨α-甲酰基辅酶A消旋酶(P504S)在前列腺癌(PCa)组织中的表达及其与血清PSA的关系.方法 采用免疫组织化学方法 检测P504S在PCa(36例)、前列腺高分级上皮样内瘤样病变(HG-PIN,20例)及良性前列腺增生(20例)组织中的表达,探讨其在PCa中的表达水平与血清PSA水平的关系.结果 36例PCa组织标本中,P504S的表达阳性率为72.2%(26/36).20例HG-PIN组织中P504S的表达阳性率为55.0%(11/20),20例良性前列腺增生组织中均未见阳性表达.高分化、中分化、低分化PCa组织中P504S的阳性表达率分别为44.4%、72.2%、100.0%.P504S表达与PCa恶性程度呈正相关(P＜0.05),与患者血清PSA水平无明显相关(P＞0.05).结论 P504S基因表达与Pea的分级密切相关.     

低氧诱导因子1α及血管内皮生长因子在前列腺癌中的表达及意义

目的:观察低氧诱导因子1α(H IF-1α)及血管内皮生长因子(VEGF)在前列腺癌(PCa)中的表达及意义。方法:32例PCa患者,根据G leason评分,将≥7分者设为高G leason评分组(n=12),<7分者为低G leason评分组(n=20)。良性前列腺增生(BPH)16例,BPH伴高级别前列腺上皮内瘤(PIN)15例,正常前列腺组织(NP)12例。采用免疫组化染色CD34观察各组组织中微血管密度(MVD)及H IF-1α、VEGF的表达情况。结果:PCa、PIN中H IF-1α阳性表达率分别为62.5%、60.0%,较BPH(6.3%)及NP(0)高,差异有统计学意义(P<0.05)。PCa、PIN中VEGF阳性表达率分别为78.1%、73.3%,较BPH(18.7%)及NP(8.3%)高,差异亦有统计学意义(P<0.05)。PCa的MVD为66.9±18.0,明显高于BPH(28.3±6.9)及NP(15.3±2.9)(P<0.05)。高G leason评分组H IF-1α、VEGF阳性率及MVD值均高于低G leason评分组,差异均有显著性(P<0.05)。结论:H IF-1α及VEGF过表达是PCa形成的早期事件,与PCa密切相关。     

survivin和GRIM-19在前列腺癌组织中的表达

目的:探讨survivin和GRIM-19在前列腺癌组织中的表达及意义。方法:应用免疫组化、RT-PCR和Western印迹法检测survivin和GRIM-19在正常前列腺(NP)组织、良性前列腺增生(BPH)组织和前列腺癌(PCa)组织中的表达情况。结果:免疫组化结果显示survivin在NP、BPH和PCa组织中的表达率分别为6.25%、18.18%和90.62%(P<0.01);GRIM-19的表达率分别为87.50%、81.82%和9.37%(P<0.01)。半定量RT-PCR结果显示,在NP和BPH组织未检测到survivinmRNA表达,而PCa组织可检测到survivinmRNA高表达。Western印迹结果证实,在NP和BPH组织中有微量的survivin蛋白表达;而PCa组织可检测到survivin蛋白高表达;在NP和BPH组织中GRIM-19蛋白表达强阳性,而PCa组织中只有微量表达,两者比较差异均有显著性(P<0.01)。结论:survivin和GRIM-19的表达可能与PCa的发生密切相关。     

凋亡抑制基因bcl-2在前列腺组织中的表达

目的　探讨前列腺组织中bcl 2基因表达的意义。　方法　采用核酸分子原位杂交技术 ,对 11例胎儿和 2 7例成人尸体前列腺组织、6 0例良性前列腺增生患者前列腺组织中bcl 2基因mRNA表达进行检测。　结果　 9例胎儿前列腺组织bcl 2阳性表达于胚芽上皮细胞 ,其中轻度阳性8例、中度 1例 ,呈弥漫分布 ,染色浅淡。 17例成人正常前列腺组织bcl 2阳性表达于腺上皮基底细胞 ,阳性率 6 3.0 %。分泌细胞阳性表达者 9例 ;高倍镜下见细胞浆染色 ,较淡。 5 0例增生前列腺组织bcl 2阳性表达于腺上皮基底细胞 ,阳性率 83.4 % ;分泌上皮细胞阳性表达 34例 (5 6 .7% ) ;高倍镜下染色均见于细胞浆。增生组前列腺基底细胞、分泌上皮细胞bcl 2阳性表达均高于正常前列腺组 (χ2=4 .36 ,χ2 =4 .0 6 ) ,差别有显著性意义 (P <0 .0 5 ) ;正常前列腺与增生前列腺基底上皮细胞bcl 2阳性表达均高于分泌上皮细胞 (χ2 =7.5 0 ,χ2 =10 .2 0 ) ,差别有显著性意义 (P <0 .0 5 )。　结论　bcl 2基因主要表达于前列腺基底细胞 ,可能在调节前列腺上皮细胞凋亡中有重要作用     

表皮生长因子受体和转化生长因子-α在前列腺癌表达中的临床意义

目的 :探讨表皮生长因子受体 (EGFR)和转化生长因子 -α(TGFα)在前列腺癌 (PCa)中表达的临床意义。方法 :采用免疫组化法检测 43例 PCa组织和 5例正常前列腺组织中 EGFR和 TGFα的表达。结果 :正常前列腺组织中 EGFR和 TGFα分别表达在上皮细胞和基质中。 EGFR和 TGFα在 PCa细胞上的共同表达率为5 5 .8% ,二者密切相关 (r =0 .5 19) ,并与 PCa分期有关 (P <0 .0 1) ;此类患者的生存时间明显短于 EGFR和TGFα阴性表达的患者 (P <0 .0 1)。结论 :EGFR和 TGFα形成的自分泌环可能与 PCa恶化和内分泌治疗失败有关 ,同时检测它们可作为判断 PCa临床分期、预后的一个重要指标。     

External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer

BACKGROUND: Prostate stem cell antigen (PSCA), a recently identified glycosylphosphatidylinositol (GPI)-anchored cell surface protein belonging to the Thy-1/Ly-6 family of cell surface antigens, is overexpressed in human prostate cancer (PCa). Our recent data indicated that complete androgen ablation could significantly suppress PSCA mRNA expression in primarily organ-confined PCa. The effect of external beam radiotherapy (EBRT), one of the curative treatment options for localized PCa, on tumor PSCA mRNA expression has not been elucidated. The purpose of the present study was to investigate the variations in the expression levels of PSCA mRNA before and after EBRT, and further evaluate the prognostic value of PSCA in this disease. MATERIALS AND METHODS: Between January 1999 and June 2005, 87 men with clinically localized adenocarcinoma of the prostate received only EBRT with a total dose of 65-70 Gy for 6.5-7 weeks. PSCA in situ hybridization (ISH) was performed on the cancerous pretreatment biopsy or transurethral resection of prostate (TURP) tissue and post-treatment biopsy tissue of all 87 men, respectively. Tumor cytoplasmic staining of PSCA mRNA was evaluated by two independent pathologists and the differences of PSCA mRNA expression levels between the samples before and after EBRT were analyzed using the Student's t-test. Twenty-four to seventy months continuous follow-up studies after treatment were performed and aimed at assessing the correlation of PSCA mRNA expression level with biochemical relapse and/or distant metastases from the cancer. RESULTS: The percent of cells positive for PSCA mRNA by ISH labeling declined from 71.2% (0-93%) +/- 9.7% before EBRT to 30.7% (0-90%) +/- 5.3% after EBRT (P<0.001). Before EBRT, 81 of 87 cases (93.1%) were positive for PSCA mRNA labeling, however, after EBRT the percentage of positive reactivity of PSCA mRNA was decreased to 62 of 81 cases (76.5%), in which 59 men (95.2%) were found without biochemical relapse or distant metastases on follow-up. This decline in PSCA mRNA labeling was directly proportional to higher pretreatment serum PSA level, higher tumor grade (Gleason score), and higher clinical T stage. The rest 19 cases had the increased percentage of cells positive for PSCA mRNA after EBRT, in which 15 cases developed biochemical relapse and/or distant metastases from tumor on follow-up. CONCLUSIONS: We found that EBRT for PCa can significantly suppress PSCA mRNA expression and the elevated PSCA mRNA level after EBRT may be a clinically adverse predictor for tumor progression.     

The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate

BACKGROUND: Prior data showed prostate stem cell antigen (PSCA) mRNA expression in benign prostatic hyperplasia (BPH) tissues. The purpose of the present investigation was to determine whether PSCA mRNA expression in resected BPH samples was associated with the subsequent presence of cancer following transurethral resection of the prostate (TURP). METHODS: PSCA in situ hybridization was performed on the TURP-resected tissues from 288 patients, who were histopathologically confirmed BPH without cancer. All these patients were continuously followed for 9-70 months postoperatively. Univariate and multivariate cox regression analyses were used to evaluate the predictive performance of PSCA mRNA for subsequent cancer onset following TURP. RESULTS: PSCA mRNA was detected in 93/288 (32.3%) of the resected BPH specimens, with a mean positive-labeling cells of 23.8%, in which 22 patients (23.7%) were identified as having PCa on follow-up. Of 195 patients with negative expression for PSCA mRNA 2 (1.0%) were subsequently found with PCa. PSCA mRNA expression levels were directly proportional to higher Gleason score and clinical T stage. Univariate and multivariate cox regression analyses demonstrated that only PSCA mRNA expression was predictive of the subsequent cancer development after TURP, however, PSA velocity was an univariately significant but not multivariately significant predictor. CONCLUSIONS: This prospective study identifies PSCA mRNA in BPH as a significant predictor of cancer development after TURP, suggesting that PSCA may be used to identify patients who are at high risk for subsequent cancer onset following TURP for BPH and the PSCA test may be useful when applied for repeat biopsies.     

人前列腺干细胞抗原在前列腺组织中的表达

目的：克隆人前列腺干细胞抗原(PSCA)基因，并利用半定量逆转录聚合酶链反应(RT—PCR)对其组织表达谱进行分析。方法：从人前列腺癌组织提取总RNA，利用RT—PCR技术扩增出人PSCA基因编码区序列，并通过半定量RT—PCR方法检测6例人新鲜正常前列腺组织、16例前列腺增生组织及11例前列腺肿瘤组织中PSCA基因表达水平。结果：序列测定表明，克隆获得的369bp片段与文献报道的人PSCA基因编码区cDNA序列一致，PSCA为前列腺组织特异表达，在前列腺癌组织中的表达明显高于前列腺增生及前列腺正常组织。结论：PSCA是一种新的前列腺肿瘤标记物。     

Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma

BACKGROUND: Prostate stem cell antigen (PSCA) is a recently identified glycosylphosphatidylinositol (GPI)-anchored cell surface protein belonging to the Thy-1/Ly-6 family of cell surface antigens. Prior data in prostate cancers indicated that PSCA is directly regulated by androgens and PSCA expression increases with high-tumor grade, advanced stage, extracapsular invasion, and androgen-independent progression. The effect of complete androgen ablation (CAA) on tumor PSCA mRNA expression has not been elucidated. The purpose of the present study was to investigate the variations in the expression levels of PSCA mRNA before and after CAA, and further evaluate the clinically prognostic value of PSCA in human prostate carcinoma. MATERIALS AND METHODS: PSCA in situ hybridization (ISH) was performed on the cancerous pretreatment biopsy or transurethral resection of prostate (TURP) tissue of 42 men with primarily organ-confined prostate cancer before CAA, and on their tumor tissue from radical retropubic prostatectomy after CAA with bicalutamide and goserelin acetate for 3 months prior to undergoing radical prostatectomy. Tumor cytoplasmic staining of PSCA mRNA was evaluated by two independent pathologists and the differences of PSCA mRNA expression levels between the samples before and after CAA were analyzed using the Student's t-test. Thirty-six to forty months follow-up studies after radical retropubic prostatectomy were performed and aimed at assessing the correlation of PSCA mRNA expression level with local recurrences or metastases from the cancer. RESULTS: The percent of cells positive for PSCA mRNA by ISH labeling declined from 67.3% (0-89%)+/-9.4% before CAA to 33.8% (0-92%)+/-7.7% after CAA (P<0.001). Before CAA, 40 of 42 cases (95.2%) were positive for PSCA mRNA labeling, however, after CAA the percentage of positive reactivity of PSCA mRNA was decreased to 27 of 40 cases (67.5%), in which none was found with local recurrences or distant metastases after radical prostatectomy on follow-up. This decline in PSCA mRNA labeling was dependent on the original tumor grade with Gleason score of or=8: 73.4%+/-13.8% (P<0.05, respectively). The rest 13 cases had the increased percentage of cells positive for PSCA mRNA after CAA, in which 3 cases were found with local recurrences and 4 cases with distant metastases from tumor on follow-up. CONCLUSIONS: Our data demonstrate that CAA for prostate cancer can suppress PSCA mRNA expression with a tumor grade dependence and the increased expression of PSCA mRNA after CAA may be a clinically adverse predictor for tumor recurrences or distant metastases.     

全雄激素阻断治疗抑制人前列腺癌前列腺干细胞抗原mRNA的表达

目的观察全雄激素阻断（CAA）治疗前后前列腺干细胞抗原（PSCA）mRNA 表达水平的变化,并进一步评估 PSCA 在人前列腺癌的临床预后价值。方法对42例男性患者的前列腺活检组织或经尿道前列腺切除组织（包括去势前局限性前列腺癌组织和前列腺癌根治术前接受比卡鲁胺和醋酸戈舍瑞林去势治疗3个月后的癌组织）进行原位杂交。PSCA mRNA 的肿瘤细胞质染色结果由两位病理学专家独立评估,t 检验分析 CAA 前后 PSCA mRNA 表达水平的差异。前列腺癌根治术后进行36~40个月的随访,旨在评估 PSCA mRNA 表达水平与癌症局部复发或转移的相关性。结果原位杂交标记 PSCA mRNA 阳性的细胞由 CAA 前的67.3%（0~89%）±9.4%下降到 CAA 后33.8%（0~92%）±7.7%（P 〈0.001）。CAA 前95.2%（40/42）的患者 PSCA mRNA 表达阳性,而去势后阳性率降到67.5%（27/40）,且随访未发现有局部复发或远处转移。PSCA mRNA 阳性表达的减少取决于原始肿瘤的 Gleason 评分,Gleason≤6：19.3%±4.7%;Gleason=7：38.8%±7.2%;Gleason≥8：73.4%±13.8%（P 〈0.05）。其余13例,CAA 后 PSCA mRNA 阳性表达水平增加,且随访发现3例有局限复发,4例有远处转移。结论前列腺癌 CAA 可抑制 PSCA mRNA 的表达;去势治疗后 PSCA mRNA 表达的增加可成为肿瘤复发或远处转移的一个不利预测指标。     

DD3 mRNA在前列腺癌组织中定量表达分析

目的:探讨DD3基因在前列腺组织中表达的临床意义。方法:用荧光定量RT-PCR方法对21例前列腺癌(PCa)组织、27例非前列腺部位的肿瘤组织、39例良性前列腺增生(BPH)组织和15例正常前列腺组织中的DD3的表达进行了定量分析,用ROC曲线对DD3 mRNA诊断PCa的性能进行了分析。结果:27例非前列腺组织中均未检测到DD3基因的表达。DD3在PCa组、BPH组和正常前列腺组表达量的中位数分别为7.2×106、2.5×104、1.5×104拷贝/mg组织。PCa组较BPH组和正常前列腺组DD3的表达量显著增高(P<0.01),而BPH组和正常前列腺组间则差异无显著性(P>0.05)。DD3表达量与临床分期和分化程度之间均无明显相关性。DD3 mRNA曲线下面积(AUC-ROC)为0.937(95%CI:0.879～0.995)。当临界值为1.4×105拷贝/mg组织时,灵敏度、特异度、准确度、阳性预测值(PPV)、阴性预测值(NPV)、阳性拟然比(+LR)、阴性拟然比(-LR)分别为90.5%、85.0%、86.7%、76.0%、94.3%、6.03和0.11。结论:DD3 mRNA的表达仅限于前列腺组织,具有良好的组织特异性。DD3 mRNA表达在PCa组织中显著升高,在正常前列腺和BPH组织中差异无显著性。DD3 mRNA可作为PCa诊断的良好标志物,在PCa早期诊断、微转移诊断、预后判断、指导治疗等方面也具有潜在的应用价值。     

Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer

BACKGROUND: Prior data clearly demonstrated the expression of prostate stem cell antigen (PSCA) mRNA in prostatic intraepithelial neoplasia (PIN) tissues. The purpose of the present investigation was to determine whether PSCA mRNA expression was associated with the presence of cancer in this disease. METHODS: One hundred seventeen men were diagnosed with isolated PIN on initial prostate biopsy, 51 with low-grade form (LGPIN), and 66 with high-grade form (HGPIN). PSCA mRNA expression in initial PIN and subsequent cancer was examined by in situ hybridization (ISH). The differences of the PSCA mRNA expression level between the groups were analyzed by the Chi-square and Student's t-test. Univariate and multivariate logistic regression analyses were performed to evaluate the predictive performance of PSCA mRNA. RESULTS: PSCA mRNA expression level in 34 subsequent cancers was statistically increased compared with their paired PIN (P < 0.001), with a Gleason's dependence. HGPIN showed statistically high PSCA mRNA expression compared with LGPIN (P < 0.01). PSCA mRNA expression levels were significantly stronger in the initial isolated LGPIN and isolated HGPIN with subsequent cancer than those without (P < 0.001 and P < 0.001, respectively). Multivariate logistic regression analysis demonstrated that only PSCA mRNA was predictive of the onset of subsequent cancer in patients with isolated LGPIN and in those with isolated HGPIN, respectively. CONCLUSIONS: Our data identify PSCA mRNA in initial PIN as a significant predictor of subsequent cancer, suggesting that PSCA implies in prostatic tumorigenesis and may be used to identify the patients with isolated PIN who are at high risk for cancer onset in the disease process.     

核干因子在前列腺癌中的表达及其临床意义

目的:探讨核干因子(NS)基因在前列腺癌组织中的表达及其临床意义。方法:利用RT-PCR及免疫组化方法对前列腺癌、良性前列腺增生(BPH)及高级别前列腺上皮内瘤(HGPIN)组织中NS基因的表达进行检测,并探讨NS蛋白表达水平与前列腺癌患者临床指标的关系。结果:前列腺癌中NSmRNA表达水平显著高于BPH中的表达水平,NS蛋白在前列腺癌中的强阳性、阳性及弱阳性表达率分别为48.8%、36.6%及12.2%,在BPH中分别为4.0%、32.0%及56.0%,在HGPIN中分别为5.0%、25.0%及60.0%,在前列腺癌中的表达水平显著高于BPH及HGPIN中的水平,具有统计学意义(P<0.05)。NS基因表达水平与前列腺癌的分化程度呈负相关,细胞分化程度越差,NS基因表达水平越高。结论:前列腺癌中高表达NS基因,NS基因在前列腺癌的不良分化和恶性增殖中可能起着重要作用。